Hypomethylating agents and venetoclax in acute myeloid leukemia

Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.
No abstract available

Publication types

  • Interview

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azacitidine / administration & dosage
  • Azacitidine / adverse effects
  • Azacitidine / pharmacology
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic / adverse effects
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Clinical Trials as Topic
  • DNA Methylation / drug effects*
  • DNA, Neoplasm / drug effects*
  • Decitabine / administration & dosage
  • Decitabine / adverse effects
  • Decitabine / pharmacology
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Recurrence
  • Salvage Therapy
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects
  • Sulfonamides / pharmacology
  • Treatment Outcome

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • DNA, Neoplasm
  • Sulfonamides
  • Decitabine
  • Azacitidine
  • venetoclax